Virginia Economic Review

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

New or expanding companies want to know that they will be able to hire workers with the skills they need. While outside training providers offer established but generic faculty, facilities, and programs, in-house solutions allow for customization but require significant investment.

Are you a transplant, a boomerang, or a lifelong Virginian? What brought you to the Commonwealth in the first place? I’m a transplant — I was born in Missouri, then lived in Ohio, Georgia, and South Carolina. I attended Clemson University and, after earning my Ph.D.

Like his fellow Type 1 diabetics, Alec Smith took insulin every day to regulate his blood sugar.

Ashleigh de la Torre is vice president of public policy at Amazon, where she leads the company’s transportation and sustainability initiatives, supporting its operations, logistics, and delivery businesses across land, air, and sea.

Partnership With JMU, BRCC Helps Merck Fill Need for HPV Vaccines In 2019, Melissa Lubin learned that pharmaceutical giant Merck & Co., Inc., was competing for a billion-dollar expansion in Elkton, a town in the Shenandoah Valley.

During the COVID-19 pandemic, Virginia Tech's Rob Gourdie was busy investigating how to deliver medications more effectively.

Kimberly Kelly was a biomedical engineer at the University of Virginia (UVA), working on ways to diagnose pancreatic cancer, when she discovered a protein expressed by the cancer cells.